collagen type II alpha 1 chainGenealiases: ACG2 · ANFH · ANFH1 · AOM · COL11A3 · EDMMD
Q-omics provides the consensus-scored COL2A1 profile across patient tissues and cancer cell-line models. COL2A1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, COL2A1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, COL2A1 protein abundance shows 21,622 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight ACC, and HNSC as cancer lineages where COL2A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COL2A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COL2A1 survival associations across molecular data types. COL2A1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COL2A1 RNA expression–survival associations across cancer types. High COL2A1 expression shows unfavorable associations in ACC, KIRC, BLCA and THCA, but favorable associations in PAAD and UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for COL2A1 RNA expression.
This table summarizes COL2A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for COL2A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COL2A1 shows lower tumor expression in COAD and higher tumor expression in HNSC, UCEC, LIHC, LUSC and THCA. The HNSC box plot shows higher COL2A1 RNA expression in tumor versus normal tissue (log2 FC = +0.650, t-test p < 0.001).
This table shows molecular features associated with COL2A1 in patient tissues and cancer cell lines. In patient samples, COL2A1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, COL2A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
